Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Predicting RCC Outcomes After Surgery

Eur Urol; ePub 2018 Feb 2; Leibovich, et al

It appears possible to predict renal cell carcinoma (RCC) progression and death using readily available clinical and pathologic features, researchers concluded after conducting a retrospective cohort review involving >3,600 individuals. Participants had clear cell RCC (ccRCC; n=2,726), papillary RCC (papRCC; n=607), or chromophobe RCC (chrRCC; n=222). Investigators developed models based on clinicopathologic features to predict oncologic outcomes. Among the results:

  • Progression-free survival c-index was 0.83 for ccRCC, 0.77 for papRCC, and 0.78 for chrRCC.
  • Cancer-specific survival c-indexes were 0.86 for ccRCC and 0.83 for papRCC.
  • Due to only 22 deaths from RCC, cancer-specific survival was not assessed for chrRCC.
Citation:

Leibovich B, Lohse C, Cheville J, et al. Predicting oncologic outcomes in renal cell carcinoma after surgery. [Published online ahead of print February 2, 2018]. Eur Urol. doi:10.1016/j.eururo.2018.01.005.

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Must Reads in Renal Cell Carcinoma

Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4

Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021

Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001

One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617